Literature DB >> 455624

Reentrant ventricular arrhythmias in the late myocardial infarction period. 7. Effect of verapamil and D-600 and the role of the "slow channel".

N El-Sherif, R Lazzara.   

Abstract

Reentrant ventricular arrhythmias (RVA) were analyzed in dogs 3--7 days after ligation of the anterior descending coronary artery using averaged "composite" recordings of electrical activity of reentrant pathways (RP) from the epicardial surface of the infarction zone (IZ). Verapamil (V) and D-600 (D) (0.2--0.5 mg/kg i.v.) resulted in slight-to-moderate improvement of conduction in RP with abolition of spontaneous RVA and RVA initiated by premature depolarizations. The effect of V was not blocked by pretreatment with propranolol (0.5 mg/kg i.v.). Using a standard microelectrode technique and strips of epicardial muscle from the IZ, D (0.5--1 X 10(-6) g/ml) slightly improved the upstroke velocity and membrane responses of depressed ischemic cells. In contrast, tetrodotoxin (5 X 10(-7) g/ml) further depressed or abolished action potentials of ischemic cells. We conclude: 1) the moderate antiarrhythmic effect of V and D on RVA is the result of improved conduction in RP; 2) this action is partly explained by improvement of a depressed sodium channel and is not related to catecholamine release; 3) slow-response action potentials play no significant role in the genesis of ischemia-related RVA, which probably results from depression of the fast response.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455624     DOI: 10.1161/01.cir.60.3.605

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

Review 1.  [Electrophysiological classification of newer antiarrhythmic drugs (author's transl)].

Authors:  W Schmitz
Journal:  Klin Wochenschr       Date:  1980-09-15

2.  Electrophysiological effects of diltiazem, nifedipine and Ni2+ on the subepicardial muscle cells of canine heart under the condition of combined hypoxia, hyperkalemia and acidosis.

Authors:  S Kimura; H Nakaya; M Kanno
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

Review 3.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 4.  The role of calcium in the ischemic myocardium.

Authors:  W G Nayler
Journal:  Am J Pathol       Date:  1981-02       Impact factor: 4.307

Review 5.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

Review 6.  Verapamil in arrhythmia.

Authors:  D M Krikler
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

7.  Effects of verapamil on ventricular tachycardias possibly caused by reentry, automaticity, and triggered activity.

Authors:  R J Sung; W A Shapiro; E N Shen; F Morady; J Davis
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

8.  Limitation of myocardial necrosis with verapamil during sustained coronary occlusion in the closed-chest dog.

Authors:  J G Kingma; D M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

9.  Effects of calcium antagonists on the alternation of the ST-T complex and associated conduction abnormalities during coronary occlusion in dogs.

Authors:  H Hashimoto; M Nakashima
Journal:  Br J Pharmacol       Date:  1981-10       Impact factor: 8.739

10.  Effects of beta-adrenergic blockade on verapamil-responsive and verapamil-irresponsive sustained ventricular tachycardias.

Authors:  R J Sung; E C Keung; N X Nguyen; E C Huycke
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.